newsfilter
← Latest News
Business Wire·

BeiGene's BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL

Designation supported by promising safety and efficacy data from Phase 1/2 study in heavily pretreated patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma